Wendy Yang

TL;DR: It is suggested that NSC migration can be extensive, even in the adult brain and along nonstereotypical routes, if pathology is present, and the adjunctive use of inherently migratory NSCs as a delivery vehicle for targeting therapeutic genes and vectors to refractory, migratory, invasive brain tumors is suggested.

TL;DR: It is demonstrated that vascular endothelial growth factor (VEGF) is able to induce a long-range attraction of transplanted human NSCs from distant sites in the adult brain and indicates that tumor-upregulated VEGF and angiogenic-activated microvasculature are relevant guidance signals for NSC tropism toward brain tumors.

TL;DR: The novel use of intravascularly administered NSCs as an effective delivery vehicle to target and disseminate therapeutic agents to invasive tumors of neural and nonneural origin, both within and outside of the brain are suggested.

TL;DR: It is demonstrated for the first time that IGF-1 attenuates the pathological activity of non-neuronal cells that contribute to disease progression and attenuates glial cell-mediated release of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO).

TL;DR: In the therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden, providing proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma head metastases.